Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs insulin glargine in type 2 diabetes inadequately controlled on metformin ± sulfonylurea
CTR20191601Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20191601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191601.